Inflection Biosciences

Inflection Biosciences is a private, pre-revenue biotech developing novel dual PIM/PI3K kinase inhibitors for oncology and inflammatory diseases. Its lead asset, IBL-202, is in pre-clinical development for aggressive B-cell malignancies and T-cell lymphoma, while AUM302 (IBL-302) is partnered with AUM Biosciences. The company leverages a network of academic collaborations, including a foundational license from the Spanish National Cancer Research Centre (CNIO), and has secured non-dilutive funding from the EU's Horizon 2020 program.

Rational design of first-in-class, dual mechanism small molecule kinase inhibitors, primarily targeting synergistic combinations of PIM kinase and PI3K pathways to overcome resistance mechanisms in cancer.

Inflection competes in the targeted oncology space against approved PI3K inhibitors (e.g., Gilead's Zydelig, TG Therapeutics' Ukoniq) and numerous clinical-stage PIM kinase inhibitors. Its differentiation lies in the first-in-class dual PIM/PI3K inhibition, aiming to overcome resistance seen with single-pathway agents.